Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH-Reference-Cited by-同舟云学术

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

Published:2011-11-11 Issue:12 Volume:12 Page:1300-1305
ISSN:1469-221X
Container-title:EMBO reports
language:en
Short-container-title:EMBO Rep

Author:

Surdo Paola Lo¹,Bottomley Matthew J¹,Calzetta Alessandra¹,Settembre Ethan C²,Cirillo Agostino¹,Pandit Shilpa³,Ni Yan G³,Hubbard Brian³,Sitlani Ayesha³,Carfí Andrea¹

Affiliation:

1. Department of Biochemistry and Molecular Biology, IRBM P. Angeletti Via Pontina Km 30.600 Pomezia Rome I‐00040 Italy

2. Children's Hospital, Enders Building 320 Longwood Avenue Boston Massachusetts 02132 USA

3. Division of Cardiovascular Diseases, Merck Research Laboratories 126 E. Lincoln Avenue Rahway New Jersey 07065 USA

Publisher

EMBO

Subject

Genetics,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1038/embor.2011.205

Reference35 articles.

1. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

2. Mechanism of Low Density Lipoprotein (LDL) Release in the Endosome

3. Cooperation between Fixed and Low pH-Inducible Interfaces Controls Lipoprotein Release by the LDL Receptor

4. The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A

5. Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

2. Deep generative models of LDLR protein structure to predict variant pathogenicity;Journal of Lipid Research;2023-12

3. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022;Frontiers in Endocrinology;2023-11-29

4. Targeting PCSK9 to tackle cardiovascular disease;Pharmacology & Therapeutics;2023-09

5. Elevated circulating follicle stimulating hormone level is associated with dyslipidemia in male type 2 diabetes mellitus patients: A cross‐sectional study;Diabetes/Metabolism Research and Reviews;2023-08-29